← Russell 3000 cross-section

RMD RESMED INC

Trailing twelve months to 2026-06-30 · as filed 2026-08-13, not restated
Healthcare

Scale

Market cap
$34.1bn
Revenue TTM
$5.7bn
Net income TTM
$1.5bn
Free cash flow
$1.6bn
Composite score
67.4
Sector rank
#308

Valuation

P / E
22.4
EV / EBITDA
16.0
EV / sales
5.9
FCF yield
4.83%
Earnings yield vs 10-yr
-0.27pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
26.9%
EBITDA margin
36.9%
ROE
23.1%
ROIC
32.7%
Revenue growth
9.8%

Insider activity, last 90 days

Net open-market
$-4.89m
Buyers
0
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Net revenue for the three months ended March 31, 2026 was $1.4 billion, an increase of 11% compared to the three months ended March 31, 2025. Gross margin was 62.2% for the three months ended March 31, 2026 compared to 59.3% for the three months ended March 31, 2025. AND SUBSIDIARIES Management’s Discussion and Analysis of Financial Condition and Results of Operations Results of Operations Three Months Ended March 31, 2026 Compared to the Three Months Ended March 31, 2025 Net Revenue Net revenue for the three months ended March 31, 2026 increased to $1,431.4 million from $1,291.7 million for the three months ended March 31, 2025, an increase of $139.7 million or 11% (an 8% increase on a cons …RESMED INC, 10-Q, period ended 2026-03-31, filed 2026-05-01

Read the full passage →